TRODELVY Study Design

TRODELVY was evaluated vs chemotherapy in 2L and later mTNBC^1,2

ASCENT: An international, Phase 3, multicentre, open-label, randomised study

*PFS was assessed by blinded independent central review based on RECIST 1.1 criteria in patients without brain metastases (n=468).¹

ABBREVIATIONS:

2L, second line; BM-neg, brain metastases negative; ITT, intent-to-treat; IV, intravenous; mTNBC, metastatic triple-negative breast cancer; R, randomisation; RECIST, Response Evaluation Criteria in Solid Tumours;TNBC, triple-negative breast cancer; TROP-2, trophoblast cell surface antigen 2.

REFERENCES:

TRODELVY (sacituzumab govitecan) Summary of Product Characteristics. February 2023.
Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.

TRODELVY 200mg

Study Design

TRODELVY was evaluated vs chemotherapy in 2L and later mTNBC^1,2

ASCENT: An international, Phase 3, multicentre, open-label, randomised study

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

TRODELVY was evaluated vs chemotherapy in 2L and later mTNBC1,2

ASCENT: An international, Phase 3, multicentre, open-label, randomised study

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

ASCENT trial patient population1,2

529 patients with unresectable locally advanced or metastatic TNBC

TRODELVY was evaluated vs chemotherapy in 2L and later mTNBC^1,2

ASCENT trial patient population^1,2